Government-Owned Inventions; Availability for Licensing, 77882-77883 [2010-30640]
Download as PDF
<![CDATA[
77882
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices
information collection that has been
extended, revised, or implemented on or
after October 1, 1995 unless it displays
a currently valid OMB control number.
Proposed Collection
Title: Recruitment and Screening for
the Insight into Determination of
Exceptional Aging and Longevity
(IDEAL) Study. Type of Information
Collection Request: NEW. Need and Use
of Information Collection: The purpose
of the project is to conduct recruitment
and screening for the IDEAL Study. A
multifaceted recruitment approach will
be used to reach the target audience in
a wide variety of ways. Those who are
interested in participating in the IDEAL
study will be asked to complete a two
stage recruitment process consisting of a
telephone interview and a physical
exam. The Stage One interview consists
of questions concerning demographics,
physical ability, health status, and
medical conditions. Those who are
eligible after completing the telephone
interview will be asked to complete the
second stage of the screening process.
The physical examination is a modified
version of the full BLSA assessment
protocol consisting of the following
components: General appearance; vital
signs; chest and heart auscultation;
sensory systems including vision,
hearing, sensory proprioception,
neuropathy and balance; and movement
and strength of the upper and lower
extremities. In addition the potential
Number of
respondents
Type of respondent
participant will also be asked to
complete physical performance tests,
cognitive exams, an electrocardiogram
and a blood draw. Frequency of
Response: Once. Affected Public:
Individuals or households. Type of
Respondents: Healthy individuals who
are at least 80 years of age. The annual
reporting burden is as follows:
Estimated Number of Respondents:
1,500; Estimated Number of Responses
per Respondent: 1; Average Burden
Hours per Response: 0.833; and
Estimated Total Annual Burden Hours
Requested: 701. There is no annualized
cost to respondents. There are no
Capital costs to report. There are no
Operating or Maintenance Costs to
report.
Frequency of
response
Average time
per response
Annual hour
burden
Individuals who complete the phone interview ..............................................
Individuals who complete the physical exam ................................................
1,500
*300
1
1
0.167
1.5
251
450
Totals ..................................................................................................
1,500
........................
..........................
701
srobinson on DSKHWCL6B1PROD with NOTICES
*These individuals are included in the 1,500 above.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and or suggestions regarding
the item(s) contained in the notice,
especially regarding the estimated
public burden and associated response
time should be directed to the: Office of
Management and Budget, Office of
Regulatory Affairs, OIRA
submission@omb.eop.gov or by fax to
202–395–6974. Attention: Desk Officer
for NIH. To request more information on
the proposed project or obtain a copy of
the data collection plans and
instruments, contact Dr. Luigi Ferrucci,
Principal Investigator, NIA Clinical
Research Branch, Harbor Hospital, 5th
VerDate Mar<15>2010
17:09 Dec 13, 2010
Jkt 223001
Floor, 3001 S. Hanover, Baltimore, MD
21225, or call this non-toll-free number
(410) 350–3936 or E-mail your request
including your address to:
Ferruccilu@grc.nia.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
Dated: December 6, 2010.
Melissa Fraczkowski,
Project Clearance Liaison, NIA.
[FR Doc. 2010–31376 Filed 12–13–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
SUMMARY:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Software System for Quantitative
Assessment of Vasculature in Three
Dimensional Images
Description of Invention: This
invention offered for licensing and
further development is a software
system that provides the capability of
efficiently extracting, visualizing and
quantifying three dimensional vascular
networks from medical and basic
research images. Deregulation of
angiogenesis plays a major role in a
number of human diseases, most
notably cancer. A substantial increase in
the research effort in this field over the
past decade has deepened the
understanding of the angiogenic
process. However, the lack of methods
and software to quantitatively assess
vasculature in patients has considerably
hampered the ability to directly study
the angiogenesis process, as well as to
discover and develop new therapeutics
to modulate angiogenesis. The present
E:\FR\FM\14DEN1.SGM
14DEN1
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices
invention provides new semi-automated
computer algorithms, statistical
methods and user friendly visualization
tools for rapid and intuitive quantitative
evaluation of vasculature in three
dimensional data sets obtained through
non-invasive imaging techniques such
as MRI, CT–Scans, confocal microscopy,
microCT, etc. The methods and software
embodied in this invention provide a
three dimensional quantitative
capability in the clinic as a vascular
diagnostic tool and in basic research
projects to evaluate changes in vascular
network systems.
Applications:
• Medical research for studying
angiogenesis and tumor vasculature.
• Potential applications in clinical
studies and diagnostics.
• Discovery and development of antiangiogenesis agents with application to
cancer.
• Possible application to diseases
other than cancer, such as those related
to the lymphatic system, the pulmonary
airway, the kidney filtration system.
Development Status:
• The invention is fully developed.
• The software will be readily
available if so requested.
Inventors: Enrique Zudaire,
Christopher Kurcz, Yanling Liu (NCI).
Patent Status: HHS Reference No. E–
261–2010/0—Software. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
licensing.
Licensing Contacts:
• Uri Reichman, PhD, MBA; 301–
435–4616; UR7a@nih.gov.
• Michael Shmilovich, Esq.; 301–
435–5019; ShmilovichM@mail.nih.gov.
srobinson on DSKHWCL6B1PROD with NOTICES
Compounds That Treat Malaria and
Prevent Malaria Transmission
Technology Summary: The invention
offered for licensing relates to
therapeutic compounds and related
pharmaceutical compositions that can
be used in the prevention and treatment
of malaria infection. More specifically,
the invention is drawn to compounds
that can kill malaria gametocytes to
block malaria transmission and treat
malaria infection in the non-erthtrocytic
stages, as well as therapeutic uses of
these molecules to prevent or slow the
transmission of plasmodium organisms
between mammals and eliminate or
prevent infection in mammal.
Furthermore, the compounds of the
invention are tricyclic compounds
where the side rings may be 5–7
membered rings (preferably 6membered), and the center ring may be
6–8 membered ring (preferably 7membered). Also preferable structures
VerDate Mar<15>2010
17:09 Dec 13, 2010
Jkt 223001
are ones in which the side rings are aryl
rings while the center ring is cycloalkyl
ring. The compounds of the invention
have been identified by integrating
quantitative high-throughput screening
(qHTS) with genetic mapping and in
vivo oocyst formation assay.
Applications: Prevention and
treatment of malaria infections.
Inventors: Xin-zhuan Su and Jing
Yuan (NIAID).
Patent Status: International Patent
Application No. PCT/US2010/047019
filed August 27, 2010. Priority
Application 61/237,417 filed August 27,
2009. (HHS Reference No. E–283–2009).
Licensing Status: Available for
licensing.
Licensing Contacts:
• Uri Reichman, PhD, MBA; 301–
435–4616; UR7a@nih.gov.
• Michael Shmilovich, Esq.; 301–
435–5019; ShmilovichM@mail.nih.gov.
A Universal Antigen Delivery Platform
for Enhanced Immune Response
Description of Invention: The present
invention relates to use of the rotavirus
NSP2 octamer as a universal antigen
delivery platform for presenting a high
density of neutralizing epitopes to the
immune system, a strategy for boosting
antigen immunogenicity. This
application is advanced by the welldefined structural and biochemical
properties of the octamer, its high
stability at a broad range of pH,
temperature and ionic stability, and its
ease of purification (one step) under
nondenaturing conditions. Long
conformationally-dependent antigens
are readily mounted onto the platform
by fusion to the C-terminus of NSP2, a
region of the NSP2 protein positioned
on the exposed surface of the octamer.
The platform can be expressed in and
purified from prokaryotic and
eukaryotic systems.
This technology can be used for rapid
production of subunit vaccines against a
wide range of infectious agents.
Additional uses of the technology
include the generation of delivery
platforms with mounted short peptide
antigens for use in cancer
immunotherapy, production of specific
antisera to conformationally and
nonconformationally-dependent
antigens for research purposes, and
development of epitope targets and
short peptide-antigen presentation
platforms for diagnostic assays.
Applications:
• Vaccines against pathogens.
• Cancer vaccines.
• Antigen-specific antisera.
• Multivalent targets in diagnostic
assays.
Advantages:
PO 00000
Frm 00063
Fmt 4703
Sfmt 9990
77883
• Octameric platform is stable,
efficiently expressed, and easily
purified by a single step method.
• Enables the display of multivalent
conformation-dependent epitopes.
• Effective platform for short peptides
as well as long polypeptides.
Development Status: Proof-of-concept
experiments have shown that the
octamer mounted with short peptides or
long multivalent polypeptides retains its
structural and biophysical features and
is highly effective in presenting foreign
antigens to the immune system. Ease of
purification and final protein yields of
the short or long peptide antigenmounted NSP2 octamers were
comparable suggesting that the platform
accommodates a large range of antigen
sizes. The NSP2-platform also served as
an adjuvant, significantly enhancing
immunity of the mounted peptide.
Inventors: John T. Patton (NIAID);
Zenobia F. Taraporewala (NIAID).
Relevant Publications:
1. P Schuck et al. Rotavirus
nonstructural protein NSP2 selfassembles into octamers that undergo
ligand-induced conformational changes.
J Biol Chem. 2001 Mar 30;276(13):9679–
9687. [PubMed: 11121414].
2. H Jayaram et al. Rotavirus protein
involved in genome replication and
packaging exhibits a HIT-like fold.
Nature. 2002 May 16;417(6886):311–
315. [PubMed: 12015608].
3. Z Taraporewala et al. Rotavirus
NSP2 octamer as an epitope-mounting
platform. Abstract, 23rd Annual
Meeting of the American Society for
Virology, 2004.
4. K Kearney et al. Cell-line-induced
mutation of the rotavirus genome alters
expression of an IRF3-interacting
protein. EMBO J. 2004 Oct
13;23(20):4072–4081. [PubMed:
15372078].
Patent Status: U.S. Patent Application
No. 11/293,654 filed 02 Dec 2005 (HHS
Reference No. E–322–2004/0–US–02).
Licensing Status: Available for
licensing.
Licensing Contact: Kevin W. Chang,
PhD; 301–435–5018;
changke@mail.nih.gov.
Dated: December 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–30640 Filed 12–13–10; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 75, Number 239 (Tuesday, December 14, 2010)]
[Notices]
[Pages 77882-77883]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30640]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Software System for Quantitative Assessment of Vasculature in Three
Dimensional Images
Description of Invention: This invention offered for licensing and
further development is a software system that provides the capability
of efficiently extracting, visualizing and quantifying three
dimensional vascular networks from medical and basic research images.
Deregulation of angiogenesis plays a major role in a number of human
diseases, most notably cancer. A substantial increase in the research
effort in this field over the past decade has deepened the
understanding of the angiogenic process. However, the lack of methods
and software to quantitatively assess vasculature in patients has
considerably hampered the ability to directly study the angiogenesis
process, as well as to discover and develop new therapeutics to
modulate angiogenesis. The present
[[Page 77883]]
invention provides new semi-automated computer algorithms, statistical
methods and user friendly visualization tools for rapid and intuitive
quantitative evaluation of vasculature in three dimensional data sets
obtained through non-invasive imaging techniques such as MRI, CT-Scans,
confocal microscopy, microCT, etc. The methods and software embodied in
this invention provide a three dimensional quantitative capability in
the clinic as a vascular diagnostic tool and in basic research projects
to evaluate changes in vascular network systems.
Applications:
Medical research for studying angiogenesis and tumor
vasculature.
Potential applications in clinical studies and
diagnostics.
Discovery and development of anti-angiogenesis agents with
application to cancer.
Possible application to diseases other than cancer, such
as those related to the lymphatic system, the pulmonary airway, the
kidney filtration system.
Development Status:
The invention is fully developed.
The software will be readily available if so requested.
Inventors: Enrique Zudaire, Christopher Kurcz, Yanling Liu (NCI).
Patent Status: HHS Reference No. E-261-2010/0--Software. Patent
protection is not being pursued for this technology.
Licensing Status: Available for licensing.
Licensing Contacts:
Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
Michael Shmilovich, Esq.; 301-435-5019;
ShmilovichM@mail.nih.gov.
Compounds That Treat Malaria and Prevent Malaria Transmission
Technology Summary: The invention offered for licensing relates to
therapeutic compounds and related pharmaceutical compositions that can
be used in the prevention and treatment of malaria infection. More
specifically, the invention is drawn to compounds that can kill malaria
gametocytes to block malaria transmission and treat malaria infection
in the non-erthtrocytic stages, as well as therapeutic uses of these
molecules to prevent or slow the transmission of plasmodium organisms
between mammals and eliminate or prevent infection in mammal.
Furthermore, the compounds of the invention are tricyclic compounds
where the side rings may be 5-7 membered rings (preferably 6-membered),
and the center ring may be 6-8 membered ring (preferably 7-membered).
Also preferable structures are ones in which the side rings are aryl
rings while the center ring is cycloalkyl ring. The compounds of the
invention have been identified by integrating quantitative high-
throughput screening (qHTS) with genetic mapping and in vivo oocyst
formation assay.
Applications: Prevention and treatment of malaria infections.
Inventors: Xin-zhuan Su and Jing Yuan (NIAID).
Patent Status: International Patent Application No. PCT/US2010/
047019 filed August 27, 2010. Priority Application 61/237,417 filed
August 27, 2009. (HHS Reference No. E-283-2009).
Licensing Status: Available for licensing.
Licensing Contacts:
Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
Michael Shmilovich, Esq.; 301-435-5019;
ShmilovichM@mail.nih.gov.
A Universal Antigen Delivery Platform for Enhanced Immune Response
Description of Invention: The present invention relates to use of
the rotavirus NSP2 octamer as a universal antigen delivery platform for
presenting a high density of neutralizing epitopes to the immune
system, a strategy for boosting antigen immunogenicity. This
application is advanced by the well-defined structural and biochemical
properties of the octamer, its high stability at a broad range of pH,
temperature and ionic stability, and its ease of purification (one
step) under nondenaturing conditions. Long conformationally-dependent
antigens are readily mounted onto the platform by fusion to the C-
terminus of NSP2, a region of the NSP2 protein positioned on the
exposed surface of the octamer. The platform can be expressed in and
purified from prokaryotic and eukaryotic systems.
This technology can be used for rapid production of subunit
vaccines against a wide range of infectious agents. Additional uses of
the technology include the generation of delivery platforms with
mounted short peptide antigens for use in cancer immunotherapy,
production of specific antisera to conformationally and
nonconformationally-dependent antigens for research purposes, and
development of epitope targets and short peptide-antigen presentation
platforms for diagnostic assays.
Applications:
Vaccines against pathogens.
Cancer vaccines.
Antigen-specific antisera.
Multivalent targets in diagnostic assays.
Advantages:
Octameric platform is stable, efficiently expressed, and
easily purified by a single step method.
Enables the display of multivalent conformation-dependent
epitopes.
Effective platform for short peptides as well as long
polypeptides.
Development Status: Proof-of-concept experiments have shown that
the octamer mounted with short peptides or long multivalent
polypeptides retains its structural and biophysical features and is
highly effective in presenting foreign antigens to the immune system.
Ease of purification and final protein yields of the short or long
peptide antigen-mounted NSP2 octamers were comparable suggesting that
the platform accommodates a large range of antigen sizes. The NSP2-
platform also served as an adjuvant, significantly enhancing immunity
of the mounted peptide.
Inventors: John T. Patton (NIAID); Zenobia F. Taraporewala (NIAID).
Relevant Publications:
1. P Schuck et al. Rotavirus nonstructural protein NSP2 self-
assembles into octamers that undergo ligand-induced conformational
changes. J Biol Chem. 2001 Mar 30;276(13):9679-9687. [PubMed:
11121414].
2. H Jayaram et al. Rotavirus protein involved in genome
replication and packaging exhibits a HIT-like fold. Nature. 2002 May
16;417(6886):311-315. [PubMed: 12015608].
3. Z Taraporewala et al. Rotavirus NSP2 octamer as an epitope-
mounting platform. Abstract, 23rd Annual Meeting of the American
Society for Virology, 2004.
4. K Kearney et al. Cell-line-induced mutation of the rotavirus
genome alters expression of an IRF3-interacting protein. EMBO J. 2004
Oct 13;23(20):4072-4081. [PubMed: 15372078].
Patent Status: U.S. Patent Application No. 11/293,654 filed 02 Dec
2005 (HHS Reference No. E-322-2004/0-US-02).
Licensing Status: Available for licensing.
Licensing Contact: Kevin W. Chang, PhD; 301-435-5018;
changke@mail.nih.gov.
Dated: December 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-30640 Filed 12-13-10; 8:45 am]
BILLING CODE 4140-01-P
